Descriptive statistics of the cohort
| Deleterious mutation | |||
|---|---|---|---|
| Yes | No | p Value | |
| Age | |||
| At primary diagnosis | 64 | 66 | 0.047 |
| At ADT | 69.4 | 69.5 | 0.958 |
| At the development of mCRPC | 73.9 | 73.7 | 0.923 |
| Family history | |||
| Yes | 10 | 45 | 0.785* |
| No | 3 | 11 | |
| Histology | |||
| Adenocarcinoma | 5 | 28 | 0.877† |
| Poorly differentiated carcinoma NOS | 1 | 8 | |
| Small-cell carcinoma | 0 | 1 | |
| Unknown | 7 | 20 | |
| Gleason score | |||
| 7 | 0 | 2 | 0.054* |
| 8 | 0 | 15 | |
| 9 | 2 | 6 | |
| 10 | 4 | 13 | |
| NS | 7 | 21 | |
*Linear model ANOVA.
†Pearson's χ2 test.
ADT, androgen deprivation therapy; mCRPC, metastatic castrate-resistant prostate cancer; NS, not scored.